Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib and Obinutuzumab in Untreated Follicular Lymphoma
NCT02689869Phase 2Unknown
- Sponsor
- Ludwig Maximilian University of Munich
- Start
- Apr 2016
- Primary completion
- Apr 2022
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib, obinutuzumab in follicular lymphoma (FL), sponsored by Ludwig Maximilian University of Munich. Status: unknown.
02
Drugs
ibrutinibobinutuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02689869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02689869.